手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
3条
与
Lilly
有关的结果
The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis
2022 年 发布于
Int J Urol
86 卷 第 1 期
Zhou W.
Liu J.
Mao D.
Hu C.
Gao D.
Antibodies
Monoclonal
Humanized/*therapeutic use
*Carcinoma
Transitional Cell/drug therapy
Humans
Prognosis
Retrospective Studies
*Urinary Bladder Neoplasms/drug therapy
Metastatic urothelial carcinoma
Pembrolizumab
Prognostic factor
Janssen
and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas
Bayer
Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria:
Astellas
AstraZeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Janssen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Richard Wolf
Roche
Sanochemia
Sanofi
Takeda
Urogen. Consulting or Advisory Role: Astellas
AstraZeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Janssen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Richard Wolf
Roche
Sanochemia
Sanofi
Takeda
Urogen. Speakers Bureau: Astellas
Astra
Zeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Janssen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Richard Wolf
Roche
Sanochemia
Sanofi
Takeda
Urogen
Movember Foundation. The other authors declare no conflicts of interest
associated with this manuscript.
文献简介
原文链接
吉西他滨较丝裂霉素治疗 TURBT 后非肌层浸润性膀胱癌的复发率低、毒副作用小 : 基于随机对照试验的荟萃分析
2021 年 发布于
PeerJ
60 卷 第 5 期
彭磊
蒙春杨
李金泽
李云祥
李进铭
赵攀
韦堂墙
伍季
Adult
Aged
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
B7-H1 Antigen/antagonists & inhibitors
Carcinoma/*drug therapy/immunology/mortality/pathology
Clinical Decision-Making
Female
Humans
Immune Checkpoint Inhibitors/adverse effects/*therapeutic use
Male
Middle Aged
Patient Selection
Progression-Free Survival
Time Factors
Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology
Urothelium/*drug effects/immunology/pathology
Immune-checkpoint inhibitor
Meta-analysis
Programmed death-ligand 1
Urothelial carcinoma
interests/personal relationships which may be considered as potential competing
interests: The authors certify that all conflicts of interest
including specific
financial interests and relationships and affiliations relevant to the subject
matter or materials
discussed in the article are listed as follows: Shahrokh
Shariat owns or co-owns the following patents: methods to determine prognosis
after therapy for prostate cancer. Granted 2002-09-06. Methods to determine
prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic
methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas:
urinary marker for the detection of bladder transitional cell carcinoma. Granted
2010-07-20. He has a consulting or advisory role for the following: Astellas
Astra Zeneca
Bayer
BMS
Cepheid
Ferring
Ipsen
Jansen
Lilly
MSD
Olympus
Pfizer
Pierre Fabre
Roche
Sanochemia
Sanofi
Takeda
Urogen and Wolff. All
remaining authors have declared no conflicts of interest.
文献简介
原文链接
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text
2021 年 发布于
Can Urol Assoc J
15 卷 第 8 期
Bhindi B.
Kool R.
Kulkarni G. S.
Siemens D. R.
Aprikian A. G.
Breau R. H.
Brimo F.
Fairey A.
French C.
Hanna N.
Izawa J. I.
Lacombe L.
McPherson V.
Rendon R. A.
Shayegan B.
So A. I.
Zlotta A. R.
Black P. C.
Kassouf W.
Guidelines as Topic
Humans
Immunotherapy/*methods
Societies
Medical/*standards
Urinary Bladder Neoplasms/*drug therapy
antineoplastic protocols
immunotherapy
urinary bladder neoplasms
urologic neoplasms
Pfizer
AstraZeneca
Nektar
Seattle Genetics
DragonFly Therapeutics
Non-CME
services: Genentech
AstraZeneca
Merck
Seattle Genetics
Contracted research:
Genentech
Merck
AstraZeneca
Nektar
Seattle Genetics
Immunomedics.
PCB─Consulting fees: AbbVie
Asieris Pharmaceuticals
Astellas
AstraZeneca
Bayer
Biosyent
Bristol-Myers Squibb
EMD Serono
Ferring
Fergene
H3
Biomedicine
Janssen
Merck
Roche
Sanofi
TerSera
Urogen
Contracted research:
iProgen. MTC─Consulting fees: Pfizer
EMD Serono
AstraZeneca
Exelixis
Eisai
Seattle Genetics
Astellas
Contracted research: Exelixis
Pfizer/EMD Serono
Janssen
Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus
group 2020. MDG─Consulting fees: Inovio
NuMab
Janssen
Merck
GlaxoSmithKline
Genentech
Bristol-Myers Squibb
Seattle Genetics
Dracen
Dragonfly
Astellas
Novartis
Pfizer
AstraZeneca
Incyte
Dendreon
Eli
Lilly
EMD Serono
Aileron
Therapeutics
Ownership interest: Rappta Therapeutics
NPI: 1639140668.
PG─Consulting fees: AstraZeneca
Dyania Health
EMD Serono
Immunomedics
Janssen
Merck
Mirati Therapeutics
Genentech
Pfizer
Seattle Genetics
Contracted Research: Bavarian Nordic
Bristol-Myers Squibb
Clovis Oncology
Debiopharm
Immunomedics
Pfizer
Merck
QED Therapeutics
GlaxoSmithKline
Kure
It Cancer Research
Mirati Therapeutics. SG─Consulting fees: Merck
Bristol-Myers
Squibb
Janssen
Seattle Genetics
AstraZeneca
Contracted research:
Bristol-Myers Squibb
Pfizer
Non-CME services: Exelixis. CJH─Consulting fees:
Astellas
Bristol-Myers Squibb
Genentech
Merck
Eisai
Seattle Genetics
2bPrecise
Non-CME services: Astellas
Bristol-Myers Squibb
Genentech
Eisai
Seattle Genetics. AMK─Consulting fees: Abbott Molecular
Arquer
ArTara
Asieris
AstraZeneca
BioClin Therapeutics
Bristol-Myers Squibb
Cepheid
Cold Genesys
Eisai
Engene
Inc.
Ferring
FerGene
Imagin
Janssen
MDxHealth
Medac
Merck
Pfizer
Photocure
ProTara
Roviant
Seattle Genetics
Sessen Bio
Theralase
TMC
Innovation
US Biotest
Contracted research: Adolor
Bristol-Myers Squibb
FKD
Industries
Heat Biologics
Merck
Photocure
SWOG/NIH
SPORE
AIBCCR
Clinical
trials: FKD
Merck
Bristol-Myers Squibb
Photocure
SWOG
Adolor
Heat
Biologics
Laboratory research: NIH
SPORE
AIBCCR
Educational grant: CEC
Oncology
Editorial board: European Urology Oncology
Journal of Urology
UroToday
President of organization: International Bladder Cancer Network (IBCN)
International Bladder Cancer Group (IBCG)
IP Rights: CyPRIT (Cytokine Predictors
of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center.
LPL─Consulting fees: Pfizer Advisory Nursing board
2018
Lecture/Speaker/Expert
Panel: ASCO Bladder Program 2019
Pfizer learning day 2019
ASCO Bladder Program
Panel Member and Faculty 2019
Pfizer Learning Day Speaker 2019
BCAN Webinar
Faculty 11/2020. JJM─Consulting fees: AstraZeneca
Ferring
Janssen
Nucleix
Foundation Medicine
Contracted research: Epizyme
Tesaro
Abbvie
Teaching an
endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca
Infinity Pharma
Pfizer
Flatiron
Genentech
Merck
Seattle Genetics
Contracted research:
Astellas
Bristol-Myers Squibb
Genentech
Merck. JER─Consulting fees: Merck
Bristol-Myers Squibb
AstraZeneca
Astellas
Seattle Genetics
Boehringer
Ingelheim
Bayer
Pfizer
Roche/Genentech
Mirati
QED Therapeutics
Janssen
Pharmacyclics
GlaxoSmithKline
Contracted research/Clinical trial funding:
Seattle Genetics
Astellas
Roche/Genentech
Bayer
AstraZeneca
QED
Therapeutics. NS─Consulting fees: Amgen
Astellas
AstraZeneca
Bayer
Bristol-Myers Squibb
Dendreon
Fergene
Ferring
Janssen
Merck
Myovant
Nymox
Pfizer
Sanofi/Genzyme
Sesen Bio
Sun Pharma
Tolmar. GDS─Consulting fees:
Merck
Janssen
Ferring
Bristol-Myers Squibb
Pfizer
Genentech
Epivax
Oncology
AstraZeneca
Fidia
Cold Genesys
EnGene Bio
Aduro Biotech
Dendreon
FKD Therapies
CiClomed
Seattle Genetics
Urogen
PhotoCure. SITC staff:
SMW—Shares owned: Pacific Biosciences
Editas Medicine
EG
AK
BL
LL─Nothing to
disclose.
文献简介
原文链接